联合治疗视网膜静脉阻塞性黄斑水肿的研究进展  

Research progress in combined treatment of retinal vein occlusion-induced macular edema

作　　者：石雅文 李秀云 Shi Yawen;Li Xiuyun(Department of Ophthalmology,Affiliated Hospital of Shandong Second Medical University,Weifang 261041,Shandong Province,China)

机构地区：[1]山东第二医科大学附属医院眼科,山东省潍坊市261041

出　　处：《国际眼科杂志》2025年第4期594-599,共6页International Eye Science

基　　金：山东省自然科学基金面上项目(No.ZR2023MH069);潍坊市科技局课题项目(No.2021YX029)。

摘　　要：视网膜静脉阻塞性黄斑水肿(RVO-ME)作为视网膜静脉阻塞最威胁视功能的并发症之一,具有难治性、顽固性和反复性的特点。近年来研究发现,联合治疗优于单一治疗,既能有效减轻黄斑水肿,又能在一定程度上改善视功能,同时减少治疗次数,降低总体费用,减轻患者负担等,弥补了单一治疗模式的不足,被临床寄予厚望。文章旨在对视网膜静脉阻塞性黄斑水肿的联合治疗现状及展望作一综述。Retinal vein occlusion-induced macular edema(RVO-ME)is a severe complication of retinal vein occlusion,known for its challenging treatment,persistence,and tendency to recur.Recent studies have demonstrated that combined therapy offers advantages over single therapy,effectively reducing macular edema,enhancing visual function,decreasing the frequency of treatments,lowering overall costs,and easing the patient’s burden.This approach addresses the limitations of single treatment methods and has garnered significant clinical interest.This article reviews the current status and future prospects of combined treatments for RVO-ME.

关 键 词：视网膜静脉阻塞 黄斑水肿 联合治疗 血管内皮生长因子 激光光凝 

分 类 号：R47[医药卫生—护理学]